Short Interest in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Increases By 161.3%

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) was the recipient of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 500,700 shares, a growth of 161.3% from the January 31st total of 191,600 shares. Based on an average trading volume of 3,200,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 6.4% of the shares of the company are short sold.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP raised its position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 94.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,649 shares of the specialty pharmaceutical company’s stock after buying an additional 18,271 shares during the period. Two Sigma Investments LP owned about 0.27% of Cumberland Pharmaceuticals worth $89,000 at the end of the most recent quarter. Institutional investors and hedge funds own 15.51% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Cumberland Pharmaceuticals in a report on Friday, February 14th. They issued a “hold” rating on the stock.

Cumberland Pharmaceuticals Stock Performance

CPIX stock traded down $0.19 during trading on Friday, hitting $4.78. 17,119 shares of the company traded hands, compared to its average volume of 2,459,696. Cumberland Pharmaceuticals has a 1 year low of $1.04 and a 1 year high of $7.19. The company has a market cap of $67.12 million, a PE ratio of -6.21 and a beta of 0.12. The stock’s 50-day simple moving average is $3.34 and its 200 day simple moving average is $2.04. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.13 and a quick ratio of 0.99.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.